The safety and tolerability of botulinum toxins for the treatment of cervical dystonia

Bibliography

• JANKOVIC J, BRIN MF: Therapeutic usesof botulinum toxin. N. Engl. J. Med. (1991) 324:1186–1194.
   PubMed Web of Science ®Google Scholar
• BRASHEAR A, AMBROSIUS WT, ECKERT GJ, SIEMERS ER: Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A. Mov. Disord. (1998) 13:158–161.
   PubMed Web of Science ®Google Scholar
• BRESSMAN SB, GREENE PE: Dystonia.Curt: Treat Options Neurol (2000) 2:275–285.
   PubMedGoogle Scholar
• JANKOVIC J, NUTT JG: Blepharospasm and cranial-cervical dystonia (IVIeige's syndrome): Familial occurrence. Adv. Neurol (1988) 49:117–123.
   PubMedGoogle Scholar
• ADLER CH, KUMAR R: Pharmacological and surgical options for the treatment of cervical dystonia. Neurology (2000) 55:S9–S14.
   PubMed Web of Science ®Google Scholar
• BRASHEAR A, GORDON ME ELOVIC E et al.: Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl. J. Med. (2002) 347:395–400.
   Google Scholar
• BORG-STEIN J, PINE ZM, MILLER JR, BRIN MF: Botulinum toxin for the treatment of spasticity in multiple sclerosis. New observations. Am. I Phys. Med. Rehabil. (1993) 72:364–368.
   PubMed Web of Science ®Google Scholar
• KOMAN LA, MOONEY JF 3RD, SMITH BP, WALKER F, LEON JM: Botulinum toxin type a neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo-controlled trial. Botox study group. I Pediatr. Orthop. (2000) 20:108–115.
   PubMed Web of Science ®Google Scholar
• DODICK DW: Botulinum neurotoxin for the treatment of migraine and other primary headache disorders: From bench to bedside. Headache (2003) 43\(Supp1.1):25–33
   Google Scholar
• MATHEW NT, KAUP AO: The use of botulinum toxin type a in headache treatment. Curr. Treat. Options. Neurol (2002) 4:365–373
   PubMedGoogle Scholar
• MARIA G, CASSETTA E, GUI D, BRISINDA G, BENTIVOGLIO AR, ALBANESE A: A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. N Engl. J. Med. (1998) 338:217–220.
   PubMed Web of Science ®Google Scholar
• BONI R, KREYDEN OP, BURG G: Revivalof the use of botulinum toxin: Application in dermatology Dermatology (2000) 200:287–291
   Google Scholar
• ACQUADRO MA, BORODIC GE: Treatment of myofascial pain with botulinum a toxin. Anesthesiology (1994) 80:705–706.
   PubMed Web of Science ®Google Scholar
• AOKI KR: Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache. (2003) 43\(Supp1.1):9–15
   Google Scholar
• SCOTT AB: Botulinum toxin injection of eye muscles to correct strabismus. Trans. Am. Ophthalmol Soc. (1981) 79:734–770
   PubMedGoogle Scholar
• BRASHEAR A, LEW ME DYKSTRA DD et al.: Safety and efficacy of neurobloc (botulinum toxin type b) in type a-responsive cervical dystonia. Neurology (1999) 53:1439–1446.
   Google Scholar
• BRIN ME LEW ME ADLER CH et al.: Safety and efficacy of neurobloc (botulinum toxin type b) in type a- resistant cervical dystonia. Neurology (1999) 53:1431–1438.
   PubMed Web of Science ®Google Scholar
• GREENE PE, FAHN S: Response to botulinum toxin fin seronegative botulinum toxin a- resistant patients. Mov Disord. (1996) 11:181–184.
   PubMed Web of Science ®Google Scholar
• GREENE PE, FAHN S: Use of botulinum toxin type f injections to treat torticollis in patients with immunity to botulinum toxin type a. Mov. Disord. (1993) 8:479–483.
   PubMed Web of Science ®Google Scholar
• HATHEWAY CL: Botulism The present status of the disease. Curl: Top Microbiol Immunol. (1995) 195:55–75.
   PubMed Web of Science ®Google Scholar
• LEW ME BRASHEAR A, FACTORS. The safety and efficacy of botulinum toxin type b in the treatment of patients with cervical dystonia: Summary of three controlled clinical trials. Neurology (2000) 55:S29–S35.
   Google Scholar
• SCHIAVO G, SHONE CC, ROSSETTO 0, ALEXANDER FC, MONTECUCCO C: Botulinum neurotoxin serotype f is a zinc endopeptidase specific for vamp/synaptobrevin. J. Biol. Chem. (1993) 268:11516–11519.
   PubMed Web of Science ®Google Scholar
• CHEN R, KARP BI, HALLETT M: Botulinum toxin type f for treatment of dystonia: Long-term experience. Neurology (1998) 51:1494–1496.
   PubMed Web of Science ®Google Scholar
• DE PAIVA A, ASHTON AC, FORAN P, SCHIAVO G, MONTECUCCO C, DOLLY JO: Botulinum a like type b and tetanus toxins fulfils criteria for being a zinc-dependent protease. J. Neurochem. (1993) 61:2338–2341.
   PubMed Web of Science ®Google Scholar
• BRIN ME AOKI KR: Botulinum toixn type a: Pharmacology In: Mayer N, Simpson DM (Eds). Spasticig".• Etiology evaluation, management and the role of botulinum toxin. New York: WeMove; (2002).
   Google Scholar
• DE PAIVA A, POULAIN B, LAWRENCE GW, SHONE CC, TAUC L, DOLLY JO: A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin a revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly. J. Biol. Chem. (1993) 268:20838–20844.
   PubMed Web of Science ®Google Scholar
• SIMPSON LL: Pharmacological studies onthe subcellular site of action of botulinum toxin type a. J. Pharmacol Exp. Ther. (1978) 206:661–669.
   PubMed Web of Science ®Google Scholar
• DE PAIVA A, MEUNIER FA, MOLGO J, AOKI KR, DOLLY JO: Functional repair of motor endplates after botulinum neurotoxin type a poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals. Proc. Natl. Acad. Li. U.S.A. (1999) 96:3200–3205.
   PubMed Web of Science ®Google Scholar
• FAHN S, BRESSMAN SB, MARSDEN CD: Classification of dystonia. Adv Neurol (1998) 78:1–10.
   PubMedGoogle Scholar
• ALBANESE A, BENTIVOGLIO AR, COLOSIMO C, GALARDI G, MADERNA L, TONALI P: Pretarsal injections of botulinum toxin improve blepharospasm in previously unresponsive patients. I Neurol Neurosurg. Psychiatry (1996) 60:693–694.
   PubMed Web of Science ®Google Scholar
• BLITZER A, BRIN ME GREENE PE, FAHN S: Botulinum toxin injection for the treatment of oromandibular dystonia. Ann. Otol Rhino] Laryngol (1989) 98:93–97.
   PubMed Web of Science ®Google Scholar
• BLITZER A, BRIN ME STEWART CF: Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12-year experience in more than 900 patients. Laryngoscope. (1998) 108:1435–1441.
   PubMed Web of Science ®Google Scholar
• RIVEST J, LEES AJ, MARSDEN CD: Writer's cramp: Treatment with botulinum toxin injections. Mott Disord. (1991) 6:55–59.
   PubMed Web of Science ®Google Scholar
• BRASHEAR A: The botulinum toxins in the treatment of cervical dystonia. Semia Neurol (2001) 21:85–90.
   PubMed Web of Science ®Google Scholar
• FORD B, GREENE PE, LOUIS ED et al.: Intrathecal baclofen in the treatment of dystonia. Adv. Neurol (1998) 78:199–210.
   PubMedGoogle Scholar
• BERTRAND CM: Selective peripheral denervation for spasmodic torticollis: Surgical technique, results, and observations in 260 cases. Surg. Neurol (1993) 40:96–103.
   PubMed Web of Science ®Google Scholar
• ANDALUZ N, TAHA JM, DALVI A: Bilateral pallidal deep brain stimulation for cervical and truncal dystonia. Neurology (2001) 57:557–558.
   PubMed Web of Science ®Google Scholar
• BRONTE-STEWART H: Surgical therapy for dystonia. Curr. Neurol Neurosci. Rep. (2003) 3:296–305.
   PubMedGoogle Scholar
• BRASHEAR A: Botulinum toxin type b: A new injectable treatment for cervical dystonia. Expert. Opia Investig. Drugs (2001) 10:2191–2199.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J: Blepharospasm and oromandibular-laryngeal-cervical dystonia: A controlled trial of botulinum a toxin therapy. Adv. Neurol (1988) 50:583–591.
   PubMedGoogle Scholar
• JANKOVIC J, ORMAN J: Botulinum a toxin for cranial-cervical dystonia: A double-blind, placebo-controlled study. Neurology (1987) 37:616–623.
   PubMed Web of Science ®Google Scholar
• LEW MF, ADORNATO BT, DUANE DD et al: Botulinum toxin type b: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology (1997) 49:701–707.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD: Review of botulinum toxin type a and its clinical applications in migraine headache. Expert Opia Pharmacother. (2001) 2:1649–1654.
   PubMedGoogle Scholar
• FOSTER L, CLAPP L, ERICKSON M, JABBARI B: Botulinum toxin a and chronic low back pain: A randomized, double-blind study Neurology(2001) 56:1290–1293.
   Google Scholar
• ASSESSMENT: The clinical usefulness of botulinum toxin-a in treating neurologic disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Neurology (1990) 40:1332–1336.
   PubMed Web of Science ®Google Scholar
• ALLERGAN I. PACKAGE INSERT: botox (botulinum toxin type a purified neurotoxin complex). (2000)
   Google Scholar
• ELAN PHARMACEUTICALS I. PACKAGE INSERT: myobloc botulinum toxin type b injectable solution. (2000)
   Google Scholar
• CONSKY E, LANG A: Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallett M (Eds.) Therapy with botulinum toxin. New York: Marcel Dekker, (1994) :211–237.
   Google Scholar
• O'BRIEN C, BRASHEAR A, CULLIS P et al.: Cervical dystonia severity scale reliability study. Mov. Disord. (2001) 16:1086–1090.
   Google Scholar
• COMELLA CL, JANKOVIC J, LEURGANS S, FAN W, CHMURA TA, GROUP DS: Botulinum toxin serotype a compared to b in cervical dystonia: Randomizd, double-blind, parallel study (abstract). Ann. Neurol (2004) 56:S25.
   Web of Science ®Google Scholar
• CEBALLOS-BAUMANN AO: Evidence-based medicine in botulinum toxin therapy for cervical dystonia. Neurol (2001) 248\(Suppl. 1):14–20.
   Google Scholar
• GREENE P, KANG U, FAHN S, BRIN M, MOSKOWITZ C, FLASTER E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology (1990) 40:1213–1218.
   PubMed Web of Science ®Google Scholar
• BORODIC GE, MILLS L, JOSEPH M: Botulinum a toxin for the treatment of adult-onset spasmodic torticollis. Plast. Reconstr Surg. (1991) 87:285–289.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, SCHWARTZ KS: Longitudinal experience with botulinum toxin injections for treatment of blepharospasm and cervical dystonia. Neurology (1993) 43:834–836.
   PubMed Web of Science ®Google Scholar
• Botulinum toxin a (allergan). Agn 191622,botox. Drugs RD. (1999) 2:381–382.
   Google Scholar
• JANKOVIC J, SCHWARTZ K: Botulinum toxin injections for cervical dystonia. Neurology (1990) 40:277–280.
   PubMed Web of Science ®Google Scholar
• GELB DJ, LOWENSTEIN DH, AMINOFF MJ: Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis. Neurology (1989) 39:80–84.
   PubMed Web of Science ®Google Scholar
• BLACKIE JD, LEES AJ: Botulinum toxintreatment in spasmodic torticollis. Neurol Neurosurg. Psychiatry (1990) 53:640–643.
   PubMed Web of Science ®Google Scholar
• COMELLA CL, BUCHMAN AS, TANNER CM, BROWN-TOMS NC, GOETZ CG: Botulinum toxin injection for spasmodic torticollis: Increased magnitude of benefit with electromyographic assistance. Neurology (1992) 42:878–882.
   PubMed Web of Science ®Google Scholar
• BHAUMIK S, BEHARI M: Botulinum toxin a-injection for cervical dystonia. Assoc. Physicians India (1999) 47:267–270.
   PubMedGoogle Scholar
• HAUSSERMANN P, MARCZOCH S, KLINGER C, LANDGREBE M, CONRAD B, CEBALLOS-BAUMANN A: Long-term follow-up of cervical dystonia patients treated with botulinum toxin a. Mov. Disord. (2004) 19:303–308
   PubMed Web of Science ®Google Scholar
• WISSEL J, KANOVSKY P, RUZICKA Eet al.: Efficacy and safety of a standardised 500 unit dose of dysport (clostridium botulinum toxin type a haemaglutinin complex) in a heterogeneous cervical dystonia population: Results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. Neurol (2001) 248:1073–1078.
   Google Scholar
• BRANS JW, LINDEBOOM R, SNOEK JW et al.: Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial. Neurology (1996) 46:1066–1072.
   PubMed Web of Science ®Google Scholar
• ODERGREN T, HJALTASON H, KAAKKOLA S et al: A double blind, randomised, parallel group study to investigate the dose equivalence of dysport and botox in the treatment of cervical dystonia. I Neurol Neurosurg. Psychiatry (1998) 64:6–12.
   PubMed Web of Science ®Google Scholar
• SAMPAIO C, FERREIRA JJ, SIMOES Fet al.: Dysbot: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type a-dysport and botox-assuming a ratio of 4:1. Mov. Disord. (1997) 12:1013–1018.
   Google Scholar
• POEWE W, DEUSCHL G, NEBE A et al.: What is the optimal dose of botulinum toxin a in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using dysport. German dystonia study group. I Neurol Neurosurg. Psychiatry (1998) 64:13–17.
   PubMed Web of Science ®Google Scholar
• CULLIS PA, O'BRIEN CF, TRUONG DD, KOLLER M, VILLEGAS TP, WALLACE JD: Botulinum toxin type b: An open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients. Adv. Neurol (1998) 78:227–230.
   PubMedGoogle Scholar
• JANKOVIC J, SCHWARTZ K: Response and immunoresistance to botulinum toxin injections. Neurology (1995) 45:1743–1746.
   PubMed Web of Science ®Google Scholar
• GREENE P, FAHN S, DIAMOND B: Development of resistance to botulinum toxin type a in patients with torticollis. Mov Disord. (1994) 9:213–217.
   PubMed Web of Science ®Google Scholar
• ZUBER M, SEBALD M, BATHIEN N, DE RECONDO J, RONDOT P: Botulinum antibodies in dystonic patients treated with type a botulinum toxin: Frequency and significance. Neurology (1993) 43:1715–1718.
   PubMed Web of Science ®Google Scholar
• BORODIC GE, DUANE D, PEARCE B, JOHNSON E: Antibodies to botulinum toxin. Neurology (1995) 45:204.
   PubMed Web of Science ®Google Scholar
• HANNA PA, JANKOVIC J: Mouse bioassay versus western blot assay for botulinum toxin antibodies: Correlation with clinical response. Neurology (1998) 50:1624–1629.
   PubMed Web of Science ®Google Scholar
• HANNA PA, JANKOVIC J, VINCENT A: Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. I Neurol Neurosurg. Psychiatry (1999) 66:612–616.
   PubMed Web of Science ®Google Scholar
• HAMJIAN JA, WALKER FO: Serial neurophysiological studies of intramuscular botulinum-a toxin in humans. Muscle Nerve (1994) 17:1385–1392.
   PubMed Web of Science ®Google Scholar
• KESSLER KR, BENECKE R: The ebd test-a clinical test for the detection of antibodies to botulinum toxin type a. Mov. Disord. (1997) 12:95–99.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J, VUONG KD, AHSAN J: Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology (2003) 60:1186–1188.
   PubMed Web of Science ®Google Scholar
• KESSLER KR, SKUTTA M, BENECKE R: Long-term treatment of cervical dystonia with botulinum toxin a: Efficacy, safety, and antibody frequency. German dystonia study group. J. Neurol (1999) 246:265–274.
   PubMed Web of Science ®Google Scholar
• FACTOR SA, MOLHO E, EVANS S, FEUSTEL PJ: Efficacy and safety of repeated doses of botulinum toxin type b in type a resistant and responsive cervical dystonia patients (abstract). Mov. Disord. (2004) 19:1124.
   Google Scholar
• RANOUX D, GURY C, FONDARAI J, MAS JL, ZUBER M: Respective potencies of botox and dysport: A double blind, randomised, crossover study in cervical dystonia. I Neurol Neurosurg. Psychiatry (2002) 72:459–462.
   PubMed Web of Science ®Google Scholar